DigiPath Names Cindy Orser, PhD, Chief Science Officer of DigiPath Labs - KLTV.com-Tyler, Longview, Jacksonville, Texas | ETX News

DigiPath Names Cindy Orser, PhD, Chief Science Officer of DigiPath Labs

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE DigiPath, Inc.

Dr. Orser brings over twenty years of bioscience experience to her new role, where she will oversee the creation of cutting-edge botanical nutraceutical testing labs.

LAS VEGAS, June 10, 2014 /PRNewswire/ -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a life sciences company that creates digital pathology solutions and is focusing on the botanical nutraceutical industry, is pleased to announce the appointment of Dr. Cindy Orser, PhD, to its executive team at DigiPath Labs.

DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath, Inc. digital pathology portfolio includes PathScope(TM), PathCloud(TM), PathReview(TM), and PathConsult(TM) digital platforms to share and store archive tissue images. ...

As Chief Science Officer, Dr. Orser will be responsible for:

  • Designing the model concept best-in-class botanical nutraceutical testing lab with state-of-the-art equipment that ensures testing consistency and compliance with FDA standards.
  • Creating industry leading, standardized botanical nutraceutical testing protocols that are in compliance with FDA and CLEA standards.
  • Developing training curriculum, instructional materials and overseeing DigiPath Labs personnel training.
  • Providing scientific, technical and regulatory guidance to the executive management team.
  • Communicating and consulting with government officials.

"With a passion for innovation and an unmatched botany and scientific background, Dr. Orser was the best choice for Chief Science Officer of DigiPath Labs" said Todd Denkin, President of DigiPath, Inc., "We are all very excited to welcome her to the company as we move into botanical nutraceutical testing and development."

Dr. Orser draws from over twenty years of experience innovating in both academia and private industry. Her responsibilities have included conceptualizing, executing and managing key projects, lab benchmarking, fundraising and budgeting, staffing, managing personnel, identifying outside collaborators and directing subcontractors. She has been the liaison between several of her companies and regulatory agencies, including the FDA and CDC.

"This position excites me because of the high standards the Company is setting and the highly relevant diagnostic and regulatory experience I bring to the team" said Dr. Orser,  "I am very pleased to join the DigiPath group and believe that together we will create a cutting edge botanical nutraceutical testing process wrapped into a new laboratory concept."

Dr. Orser holds eighteen issued patents and has authored forty-one peer-reviewed publications. She was awarded a PhD from the University of California at Berkeley, where she discovered the molecular basis of bacterial ice nucleation to be a single genic trait. She received her BS in Botany from Montana State University in Bozeman.

Seven years ago, Dr. Orser founded Big Sky Biosystems Inc. As part of her role as president and CEO, she provided scientific, technical, regulatory and strategic affairs consulting for the molecular and medical diagnostics industry and the federal government.

Dr. Orser also was Co-founder and was Chief Science Officer of ASDx Biosystems, Inc., a company that developed rapid diagnostic tests for Homeland Security in conjunction with the CDC to identify biothreat agents such as ricin.

For ten years, Dr. Orser served as Corporate Senior Scientist and Head of the Biodefense/ Biotechnology Initiative at Areté Associates, a physics-based company and leader in the design, integration, and operation of in situ and remote sensing instrumentation. Prior to that, she served as Director of R&D at Adlyfe Inc., where she was responsible for the management of all aspects of bringing to market an innovative blood diagnostic for misfolded proteins associated with prion-mediated neurodegenerative disease.

Dr. Orser was also a tenured professor of biochemistry and bacteriology at the University of Idaho.

About DigiPath, Inc.

DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy.

DigiPath's digital pathology portfolio includes PathScope™, PathCloud™, PathReview™, and PathConsult™ digital platforms to share and archive tissue images. DigiPath, Inc., is expanding into new lines of business associated with the research, development, licensing, and operation of botanical and nutra-pharmaceutical products and services.

For more information about this announcement or the company, go to www.digipath.com.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events and future financial and operating performance.  The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements.  Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved.  Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. An example of such forward looking statements in this press release include statements regarding the Company developing and completing new products and revenue growth. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:

David Williams, CFO
David@DigiPath.com

Logo - http://photos.prnewswire.com/prnh/20140605/94753

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

105 West Ferguson Street
Tyler, TX 75702

FCC Public File
publicfile@kltv.com
903-597-5588
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KLTV. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.